Analyses weighting the genetic proxies for GLP1R agonism (OR per log‐odds increase in type 2 diabetes mellitus liability, 0.48; 95% CI, 0.34–0.67; P=2.87×10−5) and overall glycemic control (OR, 0.90; 95% CI, 0.87–0.93; P=1.81×10−12) by type 2 diabetes mellitus liability showed similar evidence for a reduction in heart failure risk. This evidence concerns the gene GLP1R and diabetes mellitus.